REBOOT is being conducted by the Immune Tolerance Network and sponsored by the National Institute of Allergy and Infectious Diseases (NIH funded)...
The REBOOT study will test whether a combination of two different drugs, belimumab (Benlysta®) and rituximab (Rituxan®), is safe and if this combination is more effective at blocking the immune attack on the kidney in patients with Primary Membranous Neuropathy (MN) compared to rituximab alone.